311 related articles for article (PubMed ID: 36327625)
41. A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors.
Pavone G; Motta L; Martorana F; Motta G; Vigneri P
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885875
[TBL] [Abstract][Full Text] [Related]
42. HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era.
Giugliano F; Curigliano G; Tarantino P
Eur J Cancer Prev; 2023 Mar; 32(2):149-154. PubMed ID: 36693209
[TBL] [Abstract][Full Text] [Related]
43. Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.
Grinda T; Rassy E; Pistilli B
Curr Treat Options Oncol; 2023 May; 24(5):442-465. PubMed ID: 36966267
[TBL] [Abstract][Full Text] [Related]
44. The Evolving Landscape of Immune Checkpoint Inhibitors and Antibody Drug Conjugates in the Treatment of Early-Stage Breast Cancer.
Bhardwaj PV; Abdou YG
Oncologist; 2023 Oct; 28(10):832-844. PubMed ID: 37597245
[TBL] [Abstract][Full Text] [Related]
45. Antibody-drug Conjugates for Breast Cancer Treatment.
Sheikh MS; Huang Y
Recent Pat Anticancer Drug Discov; 2022; 18(2):108-113. PubMed ID: 35909271
[TBL] [Abstract][Full Text] [Related]
46. A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
Bardia A; Hurvitz SA; Rugo HS; Brufsky A; Cortes J; Loibl S; Piccart M; Cowden J; Spears P; Carey LA
Future Oncol; 2021 Oct; 17(30):3911-3924. PubMed ID: 34467774
[TBL] [Abstract][Full Text] [Related]
47. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
[TBL] [Abstract][Full Text] [Related]
48. A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
Xu B; Ma F; Wang T; Wang S; Tong Z; Li W; Wu X; Wang X; Sun T; Pan Y; Yao H; Wang X; Luo T; Yang J; Zeng X; Zhao W; Cong XJ; Chen J
Int J Cancer; 2023 May; 152(10):2134-2144. PubMed ID: 36621000
[TBL] [Abstract][Full Text] [Related]
49. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L; Avancini A; Sposito M; Milella M; Rossi A; Pilotto S
Expert Opin Biol Ther; 2023; 23(11):1077-1087. PubMed ID: 36995069
[TBL] [Abstract][Full Text] [Related]
50. Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021.
Trapani D; Curigliano G
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S54-S57. PubMed ID: 34920925
[TBL] [Abstract][Full Text] [Related]
51. Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
Baek G; Jung L; Duong A; Gralow J
J Oncol Pharm Pract; 2022 Apr; 28(3):710-716. PubMed ID: 34761708
[TBL] [Abstract][Full Text] [Related]
52. Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis.
Püsküllüoğlu M; Rudzińska A; Pacholczak-Madej R
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188991. PubMed ID: 37758021
[TBL] [Abstract][Full Text] [Related]
53. [New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer].
Kabirian R; Da Silva A
Bull Cancer; 2022 Mar; 109(3):249-250. PubMed ID: 35094841
[No Abstract] [Full Text] [Related]
54. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
Kalinsky K; Diamond JR; Vahdat LT; Tolaney SM; Juric D; O'Shaughnessy J; Moroose RL; Mayer IA; Abramson VG; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Goswami T; Wegener WA; Bardia A
Ann Oncol; 2020 Dec; 31(12):1709-1718. PubMed ID: 32946924
[TBL] [Abstract][Full Text] [Related]
55. Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
Nicolò E; Repetto M; Boscolo Bielo L; Tarantino P; Curigliano G
Cancer J; 2022 Nov-Dec 01; 28(6):436-445. PubMed ID: 36383906
[TBL] [Abstract][Full Text] [Related]
56. Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
Sathe AG; Singh I; Singh P; Diderichsen PM; Wang X; Chang P; Taqui A; Phan S; Girish S; Othman AA
Clin Pharmacokinet; 2024 May; 63(5):669-681. PubMed ID: 38578394
[TBL] [Abstract][Full Text] [Related]
57. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
58. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Bardia A; Tolaney SM; Punie K; Loirat D; Oliveira M; Kalinsky K; Zelnak A; Aftimos P; Dalenc F; Sardesai S; Hamilton E; Sharma P; Recalde S; Gil EC; Traina T; O'Shaughnessy J; Cortes J; Tsai M; Vahdat L; Diéras V; Carey LA; Rugo HS; Goldenberg DM; Hong Q; Olivo M; Itri LM; Hurvitz SA
Ann Oncol; 2021 Sep; 32(9):1148-1156. PubMed ID: 34116144
[TBL] [Abstract][Full Text] [Related]
59. Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis.
Kathpalia M; Sharma A; Kaur N
Ann Pharmacother; 2024 Jan; 58(1):44-53. PubMed ID: 37026168
[TBL] [Abstract][Full Text] [Related]
60. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
